References
- Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;99:777–89.
- Gong H, Shi Y, Zhou L, Tao L, Shi Y, Cao W, et al. Helicobacter pylori infection of the larynx may be an emerging risk factor for laryngeal squamous cell carcinoma. Clin Transl Oncol 2012;14:905–10.
- Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: alone and together in regulation of p53. Transl Cancer Res 2012;1:88–9.
- Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83–96.
- Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, et al. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clin Cancer Res 2008;14:2527–34.
- Zhou J, Liu F, Zhang D, Chen B, Li Q, Zhou L, et al. Significance of MDM2-309 polymorphisms and induced corresponding plasma MDM2 levels in susceptibility to laryngeal squamous cell carcinoma. DNA Cell Biol 2014;33:88–94.
- Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591–602.
- Qin X, Peng Q, Tang W, Lao X, Chen Z, Lai H, et al. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk. PLoS One 2013;8:e76031.
- Ma Y, Bian J, Cao H. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One 2013;8:e56918.
- Zhuo W, Zhang L, Zhu B, Ling J, Chen Z. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PLoS One 2012;7:e41546.
- Liu G, Jiang D, Shen S, Yu L. Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis. Int J Urol 2012;19:914–20.
- Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma 2012;53:2245–52.
- Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799–807.
- Dong J, Ren B, Hu Z, Chen J, Hu L, Dai J, et al. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog 2011;50:433–8.
- Chen QW, Chen H, Cheng JS, Meng ZQ. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis. Tumour Biol 2014;35:4147–51.
- Deb SP. Function and dysfunction of the human oncoprotein MDM2. Front Biosci 2002;7:d235–43.
- Marcel V, Palmero EI, Falagan-Lotsch P, Martel-Planche G, Ashton-Prolla P, Olivier M, et al. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 2009;46:766–72.
- Vilarino-Guell C, Wider C, Ross OA, Jasinska-Myga B, Kachergus J, Cobb SA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics 2010;11:401–8.
- Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 2008;44:760–6.
- Chen X, Sturgis EM, Lei D, Dahlstrom K, Wei Q, Li G. Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res 2010;70:7199–208.